4G Pharmacare Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-06-2024
- Paid Up Capital ₹ 0.10 M
as on 16-06-2024
- Company Age 10 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.50 M
as on 16-06-2024
- Satisfied Charges ₹ 2.50 M
as on 16-06-2024
- Revenue -68.37%
(FY 2022)
- Profit -112.46%
(FY 2022)
- Ebitda -84.79%
(FY 2022)
- Net Worth -20.16%
(FY 2022)
- Total Assets -9.79%
(FY 2022)
About 4G Pharmacare
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.50 M. The company has closed loans amounting to ₹2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Bhavsing, Sanjay Kolte, Pandit Kolte, and One other member serve as directors at the Company.
- CIN/LLPIN
U24297MH2013PTC250381
- Company No.
250381
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Nov 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Navi Mumbai, Maharashtra, India
- Telephone
- Email Address
- Social Media
Who are the key members and board of directors at 4G Pharmacare?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Bhavsing  | Director | 26-Nov-2013 | Current |
| Sanjay Kolte | Director | 26-Nov-2013 | Current |
| Pandit Kolte | Additional Director | 01-Feb-2020 | Current |
| Nagesh Naik | Director | Current |
Financial Performance and Corporate Structure Insights of 4G Pharmacare.
4G Pharmacare Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 68.37% decrease. The company also saw a substantial fall in profitability, with a 112.46% decrease in profit. The company's net worth observed a substantial decline by a decrease of 20.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of 4G Pharmacare?
In 2022, 4G Pharmacare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 02 Nov 2018 | ₹4.50 M | Open |
Others Creation Date: 11 Jan 2018 | ₹2.50 M | Satisfied |
How Many Employees Work at 4G Pharmacare?
Unlock and access historical data on people associated with 4G Pharmacare, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of 4G Pharmacare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped 4G Pharmacare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
